AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9633846 — intervention group
Group type: EXPERIMENTAL
Intervention: New agents (topotecan, gemcitabine, oral etoposide, encapsulated doxorubicin)
Number of subjects: 0
Study 7886709 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent infection within 1 week before ictus or examination
Number of subjects: 197
Study 7886709 — intervention group
Group type: EXPERIMENTAL
Intervention: Febrile and subfebrile infections (> or = 37.5 degrees C)
Number of subjects: 197
Study 7886709 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection as a risk factor for cerebrovascular ischemia
Number of subjects: 197
Study 1978640 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrosine + Phenoxybenzamine
Number of subjects: 25
Study 1978640 — intervention group
Group type: COMPARATOR
Intervention: Phenoxybenzamine alone
Number of subjects: 25
Study 31784280 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper tertile pMFAP4
Number of subjects: 504
Study 31784280 — intervention group
Group type: COMPARATOR
Intervention: pMFAP4 levels
Number of subjects: 504
Study 30226087 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0
Study 30226087 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 0
Study 30226087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29938621 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ω‐3 fatty acids (2500 mg) plus nano‐curcumin (80 mg)
Number of subjects: 80
Study 29938621 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 (2500 mg)
Number of subjects: 80
Study 29938621 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-curcumin (80 mg)
Number of subjects: 80
Study 29938621 — intervention group
Group type: COMPARATOR
Intervention: Control (ω‐3 and nano‐curcumin placebo included oral paraffin oil)
Number of subjects: 80
Study 27809886 — intervention group
Group type: EXPERIMENTAL
Intervention: Small Step Program
Number of subjects: 0
Study 27809886 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 25157115 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHF patients (n = 468)
Number of subjects: 683
Study 22733286 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - identical spherical nomogram adjustments
Number of subjects: 146
Study 22733286 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B - individual adjustments of treatment sphere and treatment cylinder
Number of subjects: 146
Study 22733286 — intervention group
Group type: COMPARATOR
Intervention: Reference group - internal standard nomograms without modifications
Number of subjects: 146
Study 19557060 — intervention group
Group type: EXPERIMENTAL
Intervention: Boosting Better Breaks (BBB) break-time policy
Number of subjects: 364
Study 19557060 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 364
Study 19557060 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 364
Study 17502778 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 exclusion criteria applied to the sample of depressed adults
Number of subjects: 348
Study 17502778 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 most common exclusion criteria
Number of subjects: 348
Study 17502778 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard severity cutoff score and 4 criteria relevant to safety or diagnostic validity
Number of subjects: 348
Study 15697057 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination induction
Number of subjects: 72
Study 15697057 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction induction
Number of subjects: 72
Study 15697057 — intervention group
Group type: COMPARATOR
Intervention: Control group (no induction)
Number of subjects: 72
Study 12095666 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 74
Study 12095666 — intervention group
Group type: COMPARATOR
Intervention: Methadone (standard prison treatment)
Number of subjects: 74
Study 9640728 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing mode of the CAMCOG test
Number of subjects: 11
Study 9640728 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face mode of the CAMCOG test
Number of subjects: 11
Study 8123862 — intervention group
Group type: EXPERIMENTAL
Intervention: Bu/Cy2 regimen with monoclonal antibody-purged bone marrow
Number of subjects: 63
Study 8123862 — intervention group
Group type: COMPARATOR
Intervention: Cy/fTBI regimen with monoclonal antibody-purged bone marrow
Number of subjects: 63
Study 8123862 — intervention group
Group type: COMPARATOR
Intervention: Cy/fTBI regimen
Number of subjects: 63
Study 8123862 — intervention group
Group type: EXPERIMENTAL
Intervention: Bu/Cy2 regimen
Number of subjects: 63
Study 2775611 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium diclofenac (50 mg) dissolved in homogenized meal (C)
Number of subjects: 6
Study 2775611 — intervention group
Group type: COMPARATOR
Intervention: Sodium diclofenac (50 mg) dissolved in phosphate buffer pH 7.5 (B)
Number of subjects: 6
Study 2775611 — intervention group
Group type: COMPARATOR
Intervention: Sodium diclofenac (50 mg) dissolved in water (A)
Number of subjects: 6
Study 198055 — intervention group
Group type: EXPERIMENTAL
Intervention: 99Tcm-methylene-diphosphonate (MDP)
Number of subjects: 350
Study 198055 — intervention group
Group type: COMPARATOR
Intervention: 99Tcm-pyrophosphate (PYP)
Number of subjects: 350
Study 31589558 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 30
Study 31589558 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 30
Study 27639439 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan (HA) injections
Number of subjects: 62
Study 27639439 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Number of subjects: 62
Study 25889091 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 2
Study 25889091 — intervention group
Group type: COMPARATOR
Intervention: Glucose-lowering oral agents
Number of subjects: 2
Study 23462724 — intervention group
Group type: EXPERIMENTAL
Intervention: AGI004 4 mg then 8 mg per 24 h transdermal patch
Number of subjects: 64
Study 23462724 — intervention group
Group type: EXPERIMENTAL
Intervention: AGI004 8 mg per 24 h transdermal patch
Number of subjects: 64
Study 23462724 — intervention group
Group type: EXPERIMENTAL
Intervention: AGI004 4 mg per 24 h transdermal patch
Number of subjects: 64
Study 23462724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 21297494 — intervention group
Group type: EXPERIMENTAL
Intervention: POM3 (omega-3-acid ethyl esters, 4 g/day)
Number of subjects: 31
Study 21297494 — intervention group
Group type: COMPARATOR
Intervention: Placebo (soy oil)
Number of subjects: 31
Study 18304964 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HD-CT) with cyclophosphamide (1500 mg/m2), thiotepa (150 mg/m2), and mitoxantrone (10 mg/m2) for four consecutive days followed by stem cell transplantation
Number of subjects: 307
Study 18304964 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose chemotherapy (SD-CT) with three cycles of CMF (cyclophosphamide 500 mg/m2, methotrexate 40 mg/m2, 5-fluorouracil 600 mg/m2)
Number of subjects: 307
Study 18304964 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HD-CT versus SD-CT
Number of subjects: 307
Study 15705206 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (budesonide 400 mug)
Number of subjects: 19
Study 15705206 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 19
Study 15705206 — intervention group
Group type: COMPARATOR
Intervention: Asthmatic patients
Number of subjects: 19
Study 15705206 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 19
Study 12074350 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (2.0 mg/day)
Number of subjects: 235
Study 12074350 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (25 mg/day)
Number of subjects: 235
Study 12074350 — intervention group
Group type: COMPARATOR
Intervention: Overall hypertensive patients (no specific intervention mentioned)
Number of subjects: 235
Study 12074350 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment hypertensive patients (no specific intervention mentioned)
Number of subjects: 235
Study 10204880 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase reordering with a 10 mm acceptance window
Number of subjects: 0
Study 10204880 — intervention group
Group type: COMPARATOR
Intervention: Navigator acceptance window methods (acceptance‐rejection algorithm and diminishing variance algorithm)
Number of subjects: 0
Study 10204880 — intervention group
Group type: COMPARATOR
Intervention: Retrospective respiratory gating technique
Number of subjects: 0
Study 7486038 — intervention group
Group type: EXPERIMENTAL
Intervention: edrophonium (1 mg/kg)
Number of subjects: 30
Study 7486038 — intervention group
Group type: EXPERIMENTAL
Intervention: neostigmine (70 micrograms/kg)
Number of subjects: 30
Study 7486038 — intervention group
Group type: COMPARATOR
Intervention: placebo saline
Number of subjects: 30
Study 2208185 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 30
Study 2208185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 548840 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg twice a day)
Number of subjects: 10
Study 548840 — intervention group
Group type: COMPARATOR
Intervention: Adrenalin (epinephrine eyedrops twice a day)
Number of subjects: 10
Study 29351594 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi polysaccharide‐tetanus toxoid conjugate vaccine (Vi‐TT)
Number of subjects: 387
Study 27287823 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory tailored health information
Number of subjects: 146
Study 27287823 — intervention group
Group type: EXPERIMENTAL
Intervention: Textual tailored health information
Number of subjects: 146
Study 27287823 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no health information)
Number of subjects: 146
Study 24534097 — intervention group
Group type: EXPERIMENTAL
Intervention: FAI with cartilage lesions
Number of subjects: 15
Study 24534097 — intervention group
Group type: EXPERIMENTAL
Intervention: FAI without cartilage lesions
Number of subjects: 15
Study 24534097 — intervention group
Group type: COMPARATOR
Intervention: FAI
Number of subjects: 15
Study 24534097 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 15
Study 24346384 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive Spirometry (IS)
Number of subjects: 66
Study 24346384 — intervention group
Group type: COMPARATOR
Intervention: Deep Breathing (DB)
Number of subjects: 66
Study 20446856 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium therapy
Number of subjects: 0
Study 18983314 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading (temporary restoration placed immediately)
Number of subjects: 266
Study 18983314 — intervention group
Group type: COMPARATOR
Intervention: Early loading (temporary restoration placed 28-34 days later)
Number of subjects: 266
Study 15538594 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg/d
Number of subjects: 32
Study 15538594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12752849 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric care management plus POS intervention
Number of subjects: 451
Study 12752849 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric care management
Number of subjects: 451
Study 12752849 — intervention group
Group type: COMPARATOR
Intervention: Telephone care management
Number of subjects: 451
Study 12752849 — intervention group
Group type: COMPARATOR
Intervention: Information and referral via mail
Number of subjects: 451
Study 11106916 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA replacement (50 mg/day for 6 months)
Number of subjects: 36
Study 9322326 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentiated, individual‐based treatment program
Number of subjects: 54
Study 9322326 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 54
Study 8103763 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0
Study 8103763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 8103763 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 0
Study 8103763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0
Study 3019212 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg per day
Number of subjects: 20
Study 3019212 — intervention group
Group type: COMPARATOR
Intervention: Altizide 15 mg combined with Spironolactone 25 mg
Number of subjects: 20
Study 29532516 — intervention group
Group type: EXPERIMENTAL
Intervention: levocetirizine 5 mg
Number of subjects: 18
Study 29532516 — intervention group
Group type: EXPERIMENTAL
Intervention: diphenhydramine 50 mg
Number of subjects: 18
Study 29532516 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 27388752 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing acupressure
Number of subjects: 288
Study 27388752 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulating acupressure
Number of subjects: 288
Study 27388752 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 288
Study 24559095 — intervention group
Group type: EXPERIMENTAL
Intervention: Absent YAP1 protein expression in tamoxifen randomized patient material
Number of subjects: 144
Study 24559095 — intervention group
Group type: EXPERIMENTAL
Intervention: Low YAP1 mRNA expression in luminal A subgroup
Number of subjects: 144
Study 24559095 — intervention group
Group type: EXPERIMENTAL
Intervention: YAP1 downregulation
Number of subjects: 144
Study 24559095 — intervention group
Group type: EXPERIMENTAL
Intervention: YAP1 expression in ER+ subgroup
Number of subjects: 144
Study 24559095 — intervention group
Group type: EXPERIMENTAL
Intervention: YAP1 expression in ER- subgroup
Number of subjects: 144
Study 23157199 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy intervention
Number of subjects: 198
Study 23157199 — intervention group
Group type: EXPERIMENTAL
Intervention: STI intervention
Number of subjects: 198
Study 23157199 — intervention group
Group type: COMPARATOR
Intervention: HIV intervention
Number of subjects: 198
Study 23157199 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 198
Study 20920186 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc + Vitamin A
Number of subjects: 300
Study 20920186 — intervention group
Group type: COMPARATOR
Intervention: Zinc
Number of subjects: 300
Study 20920186 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A
Number of subjects: 300
Study 20920186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 18407013 — intervention group
Group type: EXPERIMENTAL
Intervention: Faculty-led curriculum
Number of subjects: 138
Study 18407013 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based curriculum
Number of subjects: 138
Study 18407013 — intervention group
Group type: COMPARATOR
Intervention: Established curriculum
Number of subjects: 138
Study 16168682 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg glucosamine sulfate
Number of subjects: 12
Study 16168682 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 mg glucosamine sulfate
Number of subjects: 12
Study 16168682 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,000 mg glucosamine sulfate
Number of subjects: 12
Study 16168682 — intervention group
Group type: EXPERIMENTAL
Intervention: glucosamine sulfate
Number of subjects: 12
Study 12211218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular instillation of carteolol (0.8 mg)
Number of subjects: 11
Study 12211218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal instillation of carteolol (0.8 mg)
Number of subjects: 11
Study 12211218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular instillation of carteolol
Number of subjects: 11
Study 12211218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal instillation of carteolol
Number of subjects: 11
Study 10770458 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (20 mg/kg body weight) as adjunct to neuroleptic medication
Number of subjects: 136
Study 10770458 — intervention group
Group type: COMPARATOR
Intervention: Placebo (neuroleptics alone)
Number of subjects: 136
Study 8685292 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient psychoses
Number of subjects: 326
Study 8685292 — intervention group
Group type: COMPARATOR
Intervention: Partial psychoses
Number of subjects: 326
Study 8685292 — intervention group
Group type: COMPARATOR
Intervention: Functional psychosis study
Number of subjects: 326
Study 14621840 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 monoclonal antibody
Number of subjects: 60
Study 14621840 — intervention group
Group type: COMPARATOR
Intervention: ALG (antilymphocyte globulin) polyclonal antibody
Number of subjects: 60
Study 3909732 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginally administered terbutaline sulphate (0.1 mg in 1 ml cellulose gel)
Number of subjects: 0
Study 3909732 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginally administered terbutaline sulphate (5-g medicated vaginal polymer ring containing 10% terbutaline sulphate)
Number of subjects: 0
Study 3909732 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginally administered terbutaline
Number of subjects: 0
Study 31076982 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care rotation
Number of subjects: 8
Study 31076982 — intervention group
Group type: COMPARATOR
Intervention: ACT team rotation
Number of subjects: 8
Study 30049615 — intervention group
Group type: EXPERIMENTAL
Intervention: Near glasses provided immediately (intervention group)
Number of subjects: 751
Study 30049615 — intervention group
Group type: COMPARATOR
Intervention: No glasses provided until closeout (control group)
Number of subjects: 751
Study 30049615 — intervention group
Group type: COMPARATOR
Intervention: Intervention group vs Control group
Number of subjects: 751
Study 26467635 — intervention group
Group type: EXPERIMENTAL
Intervention: Index finger strength training (n = 12)
Number of subjects: 24
Study 26467635 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 24
Study 23958607 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated body‐mind‐spirit group intervention (4 sessions, >3 hours each, once per week) + routine hospital treatment
Number of subjects: 30
Study 23958607 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital treatment only
Number of subjects: 30
Study 21862012 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 15
Study 21862012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 19930364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training for 24 weeks
Number of subjects: 129
Study 19930364 — intervention group
Group type: COMPARATOR
Intervention: Observational period followed by cognitive training
Number of subjects: 129
Study 16760324 — intervention group
Group type: EXPERIMENTAL
Intervention: GeneVac-B
Number of subjects: 173
Study 16760324 — intervention group
Group type: COMPARATOR
Intervention: Engerix-B
Number of subjects: 173
Study 14977666 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial dilation
Number of subjects: 21
Study 14977666 — intervention group
Group type: COMPARATOR
Intervention: Extraction drilling
Number of subjects: 21
Study 11700915 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified lesson stressing visual input
Number of subjects: 0
Study 11700915 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesson directly counteracting the vision misconception
Number of subjects: 0
Study 11700915 — intervention group
Group type: COMPARATOR
Intervention: Traditional college-level education
Number of subjects: 0
Study 9399388 — intervention group
Group type: EXPERIMENTAL
Intervention: Total gastrectomy
Number of subjects: 26
Study 9399388 — intervention group
Group type: COMPARATOR
Intervention: Control population
Number of subjects: 26
Study 7961198 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/L CaCO3
Number of subjects: 0
Study 7961198 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/L ofloxacin
Number of subjects: 0
Study 7961198 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg/L ciprofloxacin with 5000 mg/L CaCO3
Number of subjects: 0
Study 7961198 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/L ofloxacin with 5000 mg/L CaCO3
Number of subjects: 0
Study 7961198 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/L ciprofloxacin with 5000 mg/L CaCO3
Number of subjects: 0
Study 7961198 — intervention group
Group type: COMPARATOR
Intervention: CaCO3
Number of subjects: 0
Study 7961198 — intervention group
Group type: COMPARATOR
Intervention: ofloxacin
Number of subjects: 0
Study 7961198 — intervention group
Group type: COMPARATOR
Intervention: ciprofloxacin
Number of subjects: 0
Study 2975595 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 8 mg daily
Number of subjects: 25
Study 31553121 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient feedback condition
Number of subjects: 33
Study 31553121 — intervention group
Group type: COMPARATOR
Intervention: No patient feedback condition
Number of subjects: 33
Study 29892042 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosomes from fasting morning plasma samples after 3 months of CPAP therapy (n=24)
Number of subjects: 32
Study 29892042 — intervention group
Group type: COMPARATOR
Intervention: Exosomes from untreated patients (n=8)
Number of subjects: 32
Study 29892042 — intervention group
Group type: COMPARATOR
Intervention: Exosomes from sleep fragmentation (SF) and intermittent hypoxia (IH) exposed mice
Number of subjects: 32
Study 29892042 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosomes from CPAP treated patients
Number of subjects: 32
Study 27553385 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (CST)
Number of subjects: 248
Study 27553385 — intervention group
Group type: COMPARATOR
Intervention: Wait List (WL) Control
Number of subjects: 248
Study 26718897 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based educational intervention led by lay health workers including monthly distribution of Iron and folic acid (IFA) supplements and five monthly counseling sessions.
Number of subjects: 60